Societal Burden Associated With Type 1 Diabetes in Canada
Launched by PERIPHARM · Jan 14, 2025
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how Type 1 Diabetes (T1D) affects caregivers in Canada. Specifically, it aims to measure the impact of T1D on caregivers' work productivity, their use of healthcare services, and their overall quality of life. By gathering this information, the researchers hope to highlight the challenges that come with caring for someone with T1D, especially for parents of children who have been recently diagnosed.
To participate in this study, you need to be a parent or caregiver of a child who has been diagnosed with T1D within the last two years and be at least 18 years old. You should also live in Canada and be comfortable completing a 20-minute survey in either French or English. If you’re interested, you'll need to sign a consent form to take part. The study is currently looking for participants, and your involvement could help improve the understanding of the support needed for families managing T1D.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Parental caregiver of a child recently diagnosed (\<= 2 years) with T1D before study inclusion;
- • 2. Age ≥18 ;
- • 3. Residence in the Canada;
- • 4. Willingess to complete a 20-minute survey
- • 5. Ability to read and understand French or English;
- • 6. Signature of informed consent form (ICF)
- Exclusion Criteria:
- • 1. Participation in a clinical trial.
About Peripharm
Peripharm is a leading clinical trial sponsor dedicated to advancing pharmaceutical development through innovative research and rigorous trial management. With a focus on enhancing patient outcomes, Peripharm specializes in conducting Phase I to Phase IV clinical studies across various therapeutic areas, including oncology, neurology, and rare diseases. The organization prides itself on its commitment to scientific integrity, regulatory compliance, and collaboration, leveraging a team of experienced professionals to deliver high-quality data and insights that drive drug development forward. Through strategic partnerships and a patient-centric approach, Peripharm aims to accelerate the delivery of safe and effective therapies to the market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported